Hypercorporation Hits Upper Limit (Surging 29.84%)... Dementia-Related Stocks Diverge as ABL Bio and Rznomics Fall
Domestic listed stocks classified as dementia-related shares are showing clearly divergent moves on the morning of the 14th. Hypercorporation surged to the upper price limit, while ABL Bio and Rznomics declined. Gemvax and Nature Cell rose, underscoring the stark temperature gap among related stocks

Domestic listed stocks classified as dementia-related shares are showing clearly divergent moves on the morning of the 14th. Hypercorporation surged to the upper price limit, while ABL Bio and Rznomics declined. Gemvax and Nature Cell rose, underscoring the stark temperature gap among related stocks.
■ Hypercorporation Enters Upper Limit
According to the morning quotes on the 14th, Hypercorporation traded at 2,515 won, up 578 won (29.84%) from the previous session, recording the most prominent movement among related stocks by rising to the daily price limit. Its opening, high, and low prices were all recorded at 2,515 won.
■ ABL Bio and Rznomics Fall
In contrast, ABL Bio traded at 43,350 won, down 150 won (0.34%) from the previous session. The stock opened at 43,500 won, rose to as high as 44,250 won intraday, then fell back to 43,000 won, repeatedly fluctuating.
Rznomics is also weak. Rznomics traded at 22,000 won, down 450 won (2.00%) from the previous session. Its intraday high was 23,050 won and its low was 21,450 won. Although the stock rose early in the session, it has since turned downward.
■ Gemvax and Nature Cell Rise
Gemvax showed a relatively strong upward trend, trading at 10,160 won, up 430 won (4.42%) from the previous session. It rose to as high as 10,350 won intraday, with a low of 9,650 won.
Nature Cell also traded at 23,650 won, up 250 won (1.07%) from the previous session. It rose to as high as 24,000 won intraday before giving back some of its gains.
Meanwhile, Hyundai Pharm fell 0.79% to 7,570 won, and Hwain Pharm declined 0.10% to 10,350 won. Korea Pharmaceutical rose 0.16% to 3,095 won.
■ Why Dementia-Related Stocks Draw Attention
Market interest in dementia-related stocks is tied to the mid- to long-term industrial environment of population aging and the potential for advances in treating degenerative brain diseases. In the field of neurodegenerative diseases, including Alzheimer's, various technologies are being researched, ranging from drug development to early diagnosis, drug delivery, and suppression of disease progression.
However, not all companies grouped as related stocks pursue the same business. There are differences in each company's business structure—such as new drug development, diagnostic technologies, and existing pharmaceutical operations—and their connection to the dementia field. Therefore, directly linking a particular stock's rise to dementia drug development achievements or clinical progress requires separate verification.
In particular, bio-related stocks may see amplified price volatility depending on clinical trial results, R&D schedules, technology transfer agreements, fundraising, and company disclosures. Caution is required, as even companies in the same industry may see different materials and investor assessments reflected differently.
Hypercorporation's upper-limit surge and the declines of ABL Bio and Rznomics on this day show that stocks mentioned as dementia-related are not moving uniformly. Going forward, the progress of related companies' R&D, business performance, and new disclosures are likely to act as variables that divide stock price trends in the market.
[This article was written based on provided market data and publicly known industry characteristics, and does not constitute a recommendation to invest in any particular stock. Classification as a dementia-related stock does not imply the company's success in treatment development or business performance. Stock prices may fluctuate due to various variables, and investment decisions and their responsibility rest with the investor. AI assistance was used in the writing of this article.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] Nvidia Falls 3% While AMD Rises 5% and Broadcom 4%... Mixed Fortunes for Semiconductor Stocks on NYSE](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F623360%2Fc7c94797e342c86e%2Fvariants%2Fhero.webp&w=1920&q=75)

![Evernorth Holdings Plunges 14%... New York Stock Market on Edge Amid Nvidia Woes and Midterm Election Aftermath [Breaking]](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F10%2F614266%2F7b8d225fe874b712%2Fvariants%2Fhero.webp&w=1920&q=75)
